Trials in San Diego, California
Here are the top 10 medical studies for breast cancer in San Diego, California
Popular Filters
Phase 3 Trials
Aromatase Inhibitor
AZD9833 + Palbociclib for Breast Cancer
Recruiting1 awardPhase 3
La Mesa, California
This trial is comparing two drug combinations to treat a specific type of advanced breast cancer. One combination includes a new drug called camizestrant, and the other includes anastrozole. Both combinations also use palbociclib. The goal is to see which combination works better at slowing down the cancer.
Hormone Therapy
Giredestrant + Palbociclib vs Letrozole + Palbociclib for Breast Cancer
Recruiting1 awardPhase 3
Orange, California
This trial will compare two treatments for breast cancer: giredestrant with palbociclib, and letrozole with palbociclib. The trial will measure how well the treatments work and how safe they are.
Chemotherapy
Niraparib for Breast Cancer
Recruiting1 awardPhase 3
Orange, California
This trial is testing Niraparib, a drug that stops cancer cells from fixing their broken DNA, in patients with certain types of breast cancer that are either genetically aggressive or have signs of remaining disease after treatment. Niraparib is a drug already used for ovarian cancer and has shown promise in treating breast cancer with certain genetic markers.
Trials With No Placebo
PARP Inhibitor
Long-term Niraparib for Cancer
Recruiting1 awardPhase 2
Whittier, California
This trial provides continued access to niraparib for patients already receiving it in certain studies and aims to understand its ongoing safety. Niraparib helps stop cancer cells from repairing their DNA, which can kill the cancer. Niraparib is approved for use in ovarian cancer patients who respond to specific treatments.
Small Molecule
PC14586 for Solid Tumors
Recruiting1 awardPhase 1 & 2
La Jolla, California
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Estrogen Receptor Antagonist
Tucatinib + Trastuzumab for HER2-Positive Cancers
Recruiting1 awardPhase 2
La Jolla, California
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.